Is Ketamine Therapy Right for Treatment-Resistant Depression?

You have tried two, three, maybe five or more antidepressants. Each time, you waited the recommended six to eight weeks, hoping this would be the one that finally worked. Each time, the results fell short — partial improvement at best, intolerable side effects at worst, and often no meaningful change at all. If this describes your experience, you are not alone, and there is a clinical term for what you are going through: treatment-resistant depression.

Treatment-resistant depression (TRD) is not a failure of willpower or effort. It is a recognized clinical condition that affects a substantial portion of people with major depressive disorder, and it demands a different treatment approach. Ketamine therapy has emerged as one of the most promising options for patients in exactly this situation.

What Is Treatment-Resistant Depression?

Treatment-resistant depression is formally defined as major depressive disorder that has failed to respond adequately to at least two different antidepressant medications, each given at an appropriate dose for an adequate duration (typically 6–8 weeks per trial). The key word is "adequate" — a medication trial that was cut short due to side effects or taken at a sub-therapeutic dose does not count toward this definition.

This distinction matters because the clinical approach to TRD is fundamentally different from standard depression treatment. When two well-conducted medication trials have failed, the likelihood of the third conventional antidepressant succeeding drops significantly. The evidence suggests that each subsequent medication trial produces lower response rates, creating a diminishing-returns pattern that can leave patients feeling hopeless.

How Common Is TRD?

Treatment-resistant depression is far more common than most people realize. Research from the landmark STAR*D trial — the largest study of depression treatment ever conducted — found that approximately 30% of patients with major depressive disorder do not achieve remission even after four sequential medication trials. That translates to millions of Americans living with depression that conventional medications cannot adequately address.

The emotional toll of repeated treatment failures is substantial. Each failed medication trial is not merely a medical setback — it erodes hope. Patients begin to internalize the narrative that they are "untreatable" or that their depression is somehow their fault. This psychological burden compounds the depression itself, creating a cycle that becomes increasingly difficult to break with conventional approaches.

The Emotional Toll of Failed Treatments

Beyond the clinical definition, treatment-resistant depression carries a uniquely demoralizing quality. Every new prescription starts with cautious optimism: maybe this one will be different. The waiting period — weeks of uncertainty while the medication builds up in your system — is its own form of suffering. When improvement does not come, or when debilitating side effects force a switch, the disappointment accumulates.

Many patients with TRD report feeling dismissed by the medical system, as if their inability to respond to standard treatments reflects a personal failing rather than a biological reality. This is categorically untrue. Treatment resistance is a feature of the illness, not a reflection of the patient's character or effort. Understanding this distinction is the first step toward finding an approach that actually works.

How Ketamine Works for Treatment-Resistant Depression

Ketamine operates through an entirely different mechanism than traditional antidepressants. While SSRIs and SNRIs work by modulating serotonin and norepinephrine levels — a process that takes weeks to produce downstream changes — ketamine targets the glutamate system, the brain's primary excitatory neurotransmitter network.

At subanesthetic doses, ketamine blocks NMDA receptors on inhibitory interneurons, producing a surge of glutamate that activates AMPA receptors. This triggers a cascade of molecular events:

• BDNF release: Brain-derived neurotrophic factor promotes neuronal survival and the growth of new synaptic connections
• mTOR pathway activation: Rapidly increases protein synthesis needed to build new synapses
• Synaptogenesis: New dendritic spines form and existing synaptic connections strengthen, particularly in the prefrontal cortex

This process — the rapid rebuilding of synaptic connections that depression has degraded — is why ketamine can produce improvement in hours to days rather than the weeks required by conventional antidepressants. For patients who have waited through months or years of unsuccessful medication trials, this speed of onset represents a fundamentally different treatment experience.

Clinical Evidence: Response Rates and Outcomes

These numbers are remarkable in context. By the time a patient qualifies as treatment-resistant, the expected response rate for the next conventional antidepressant is typically below 15%. Ketamine's ability to produce clinically meaningful improvement in more than two-thirds of these patients represents one of the most significant advances in psychiatric treatment in decades.

Additionally, ketamine has demonstrated a unique capacity for rapid reduction of suicidal ideation, often within hours of the first infusion. No other currently available antidepressant can match this speed for addressing acute suicidality, making ketamine particularly valuable for patients whose depression includes thoughts of self-harm.

Eligibility Criteria at LUMUS

Not every patient with depression is an immediate candidate for ketamine therapy. At LUMUS, we follow a thorough screening process led by Dr. Michael Garcia, who is double board-certified in psychiatry and addiction medicine. This dual expertise is critical because it allows him to evaluate candidates from both a mental health and a substance safety perspective.

The Evaluation Process

Every potential ketamine patient undergoes a comprehensive psychiatric evaluation that includes:

• Medication history review: Documenting all previous antidepressant trials, dosages, durations, and reasons for discontinuation
• Diagnostic confirmation: Ensuring the primary diagnosis is accurate, as treatment resistance sometimes reflects a misdiagnosis (such as unrecognized bipolar disorder)
• Medical screening: Assessing cardiovascular health, blood pressure, liver function, and other medical factors that affect treatment safety
• Substance use assessment: Evaluating current and past substance use history to ensure safe treatment delivery
• Psychological readiness: Assessing the patient's expectations, support system, and ability to engage with aftercare recommendations

What May Disqualify a Patient

Certain conditions may preclude ketamine therapy, including uncontrolled hypertension, active psychotic disorders, active substance abuse (particularly with dissociative substances), certain cardiac conditions, and pregnancy. These exclusions exist to protect patient safety, and Dr. Garcia discusses alternatives when ketamine is not appropriate.

The Treatment Protocol: What to Expect

The standard ketamine protocol at LUMUS consists of six IV infusions administered over two to three weeks. This loading-dose approach is based on the clinical evidence showing that a series of closely spaced infusions produces more robust and longer-lasting improvement than isolated single treatments.

Each infusion session lasts approximately 40 minutes, with the full appointment (including preparation and monitoring) taking about 90 minutes. Patients remain under continuous medical supervision throughout, with vital signs monitored at regular intervals. The dosage is individualized — typically starting at 0.5 mg/kg and adjusted based on response and tolerability.

Most patients begin to notice improvement after the second or third infusion, though some experience meaningful shifts after the very first session. By the end of the six-infusion protocol, the full therapeutic effect has typically been established.

Maintenance Strategies: Sustaining Improvement

The effects of an initial ketamine series are not permanent. Without maintenance, symptoms typically begin to return within several weeks to months. This is not a failure of the treatment — it reflects the nature of treatment-resistant depression as a chronic condition that requires ongoing management.

At LUMUS, we develop individualized maintenance plans that may include:

• Booster infusions: Scheduled at gradually increasing intervals (monthly, then every 6–8 weeks) based on symptom monitoring
• Concurrent therapy: Integration with psychotherapy to consolidate the neural plasticity that ketamine creates
• Medication optimization: Some patients find that previously ineffective antidepressants work better when combined with ketamine maintenance
• Lifestyle interventions: Evidence-based recommendations for sleep, exercise, and stress management that support treatment gains

Dr. Garcia's Approach: Psychiatric Expertise Matters

One of the distinguishing features of LUMUS is that ketamine therapy is delivered under the direct supervision of a double board-certified psychiatrist. Dr. Michael Garcia's background in both psychiatry and addiction medicine means that every treatment decision is informed by deep expertise in mental health diagnosis, pharmacology, and the complexities of treatment resistance.

This matters because ketamine therapy is not a standalone intervention — it works best as part of a comprehensive psychiatric treatment plan. Dr. Garcia evaluates whether ketamine is the right tool for each patient's specific situation, adjusts protocols based on individual response patterns, and integrates ketamine with other evidence-based treatments to maximize long-term outcomes.

If you have been living with depression that has not responded to conventional treatments, you deserve to know that options exist beyond another SSRI trial. Treatment-resistant depression is not a dead end — it is a signal that your brain needs a different approach. Ketamine therapy may be that approach.